Refractory Anemia With Excess Blasts in Transformation Completed Phase 1 / 2 Trials for Idarubicin (DB01177)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096122Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaTreatment